Immunophenotyping based Lung Cancer Recognition Service
Background Service Workflow Advantages Customer Reviews FAQs Related Sections Contact Us
Creative Biolabs offers a cost-effective immunophenotyping based lung cancer recognition service to address the challenges of complex clinical trials and the development of specific antibodies for lung cancer. Our service streamlines clinical trial processes and accelerates drug discovery by providing a comprehensive analysis of the tumor microenvironment and immune cell populations. We utilize advanced recombinant DNA technology and high-throughput screening platforms to deliver critical insights for developing targeted therapies and effective patient stratification.
The Imperative for Immunophenotyping in Lung Cancer Diagnosis and Therapy
Lung cancer is the leading cause of cancer-related death worldwide. The complexity of the tumor microenvironment (TME) and the heterogeneity of lung cancer present significant challenges for accurate diagnosis and effective treatment. Traditional diagnostic methods often provide limited information, leading to suboptimal treatment decisions. As demonstrated in recent literature, immunophenotypic analysis of circulating T cells serves as a powerful liquid biopsy, offering a non-invasive method for early detection and disease monitoring. Furthermore, understanding the immune landscape is crucial for predicting patient prognosis and guiding personalized therapeutic strategies.
Fig.1 The characteristics of various forms of TIME are associated to NSCLC's responsiveness to ICI.1
Immunophenotyping based Lung Cancer Recognition Service at Creative Biolabs
Creative Biolabs' Immunophenotyping based Lung Cancer Recognition Service provides a sophisticated solution for the precise characterization of the tumor immune landscape. Our service delivers a detailed analysis of immune cell populations, their activation states, and their interactions within the TME, enabling you to make data-driven decisions for your projects. We provide actionable insights that can be used to identify new therapeutic targets, develop effective companion diagnostics, and improve patient stratification for clinical trials.
Workflow
We perform meticulous sample processing to ensure the integrity of the immune cells and nucleic acids. This includes isolating PBMCs from blood or dissociating tumor tissue to obtain individual cell suspensions, with quality control checks at each stage. The expected outcome is a high-quality, viable sample ready for analysis.
Using advanced multicolor flow cytometry, we identify and quantify various immune cell subsets (e.g., T cells, B cells, NK cells, macrophages) and their activation markers. This step provides a detailed map of the immune cell composition and phenotype.
We investigate gene expression profiles associated with immune function and tumor response. This step provides a deeper understanding of the molecular pathways involved, such as those that indicate immune subtype classifications.
Our bioinformatics specialists analyze the raw data from flow cytometry and gene expression profiling. We integrate these datasets to generate a comprehensive picture of the tumor immune microenvironment, including correlations between immunophenotype and clinical data.
We compile all findings into a comprehensive and easy-to-understand report. The expected outcome is a final deliverable that summarizes the key results and provides expert interpretation and actionable insights for your research or clinical program.
Our Service Highlights
Unparalleled Specificity and Sensitivity
Our service provides highly specific and sensitive detection of key immune cell populations and markers, crucial for distinguishing between different lung cancer subtypes.
Comprehensive Immune Profiling
We offer a holistic view of the tumor immune microenvironment, moving beyond single-marker analysis to provide a deep and interconnected understanding of immune cell interactions.
Guidance for Personalized Therapy
Our analysis assists in identifying patients most likely to respond to specific immunotherapies or chemotherapies, paving the way for truly personalized medicine.
High-Throughput Capabilities
Our platforms are designed to handle large-scale projects, allowing for efficient screening and analysis of numerous samples simultaneously.
Expert Scientific Support
Our team of experienced biologists and oncologists provides expert guidance and interpretation, ensuring you derive maximum value from your data.
Customer Reviews
[Improved Patient Stratification] - 2025, Dr. M***a K.
Using Creative Biolabs' Immunophenotyping based Lung Cancer Recognition Service in our clinical trial has significantly improved our ability to stratify patients. The detailed immune profiling allowed us to better predict which patients would respond to our novel therapeutic, leading to more focused and effective trial design.
[Enhanced Drug Target Identification] - 2024, P***r A.
The high-throughput capabilities of Creative Biolabs' platform greatly facilitated our early-stage drug discovery efforts. We were able to screen a large number of samples and identify new immune-related targets that we had not previously considered, significantly broadening our research scope.
[Valuable Data Integration] - 2025, Dr. K***e S.
We appreciated how Creative Biolabs integrated flow cytometry with gene expression data. The comprehensive analysis provided a much clearer picture of the tumor microenvironment than what we could achieve with single-platform analysis. This service has been a tremendous asset to our translational oncology research.
FAQs
Q1: What sorts of samples are suitable for the immunophenotyping service?
A1: We can analyze a wide range of biological samples, including fresh or frozen tumor tissues, peripheral blood, and other biospecimens. Our team can help you determine the optimal sample type for your specific project goals.
Q2: How can immunophenotyping data be used to assist in drug development?
A2: Immunophenotyping data can provide critical insights into the tumor microenvironment, helping you identify potential drug targets, select the most promising candidates, and develop patient-centric clinical trial strategies.
Q3: How does this service compare to standard immunohistochemistry (IHC) staining?
A3: While IHC is valuable for spatial analysis, our service provides a more quantitative and comprehensive assessment of multiple immune cell subsets and markers simultaneously, offering a deeper and more nuanced understanding of the immune landscape.
Q4: What kind of quality control measures do you have in place for the service?
A4: We employ a rigorous, multi-stage quality control process that begins with sample receipt and continues through every step of the workflow, including cell viability checks, standardized staining protocols, and data validation, to ensure the highest quality results.
Q5: Can your service be customized to our specific research needs?
A5: Yes, our service is highly flexible. We work closely with our clients to tailor the antibody panels, analysis methods, and reporting to match their unique research objectives and project requirements.
Related Sections
Why Choose Creative Biolabs
At Creative Biolabs, our deep expertise and commitment to innovation ensure that our immunophenotyping based lung cancer recognition service delivers superior results. We leverage state-of-the-art technologies and robust methodologies to provide reliable, reproducible, and clinically relevant data. Our success is built on our ability to translate complex scientific data into tangible solutions for our clients. If you want get more information about our service, please don't hesitate to get in touch with us.
Reference
-
Chi, Alexander et al. "Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade." Cancers vol. 13,12 2924. 11 Jun. 2021, doi:10.3390/cancers13122924. Distributed under Open Access License CC BY 4.0, without modification.
